MicrobiotiX strives to develop treatments
for global intractable diseases such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer
A bactericidal virus that uses bacteria as a host is called as "bacteriophage". The average size of bacteriophages is about 200 nanometers, about 1/8 of bacteria, and selectively sterilizes bacteria. This is because infection is possible only when the tail fiber of the bacteriophage is selectively adsorbed to a specific membrane protein also known as receptor protein of a bacteria. Bacteriophages can be found anywhere in the natural environment, such as soil, water, and seawater, and account for more than 90% of viruses in the human body and are harmless to the human body. In addition, it has a function of minimizing the occurrence of resistance by dramatically reducing the patient's antibiotic dose by removing the antibiotic-resistant strain and co-administration.
The Sea of Phages
Healthy people maintain a stable and balanced intestinal microbial ecosystem (microbiome). In other words, changes in the intestinal core bacteriophage and microbiome are delicately intertwined with human health (metabolites and immune system) Bacteriophages are used to balance and change intestinal microbiome through targeted bacterial removal, symbiosis with bacteria, and modulation.
Healthy Gut Phageome
Citation : Healthy human gut phageome Pilar Manrique, Benjamin Bolduc, Seth T. Walk, John van der Oost, Willem M. de Vos, Mark J. Young Proceedings of the National Academy of Sciences Sep 2016, 113 (37) 10400-10405; DOI: 10.1073/pnas.1601060113span>
Healthy people share
of key phages
Patients with Ulcerative colitis share
of key phages
Patients with Crohn’s disease share
of key phages
Our pipeline will be expanded rapidly through the analysis of 1,000 new pathogens per month and discovering effective phages to fight against them. (NGS/PCS analysis to phage vs. microbiome, taxonomy, healthy patient phage comparison) to discover candidate drug substances and build optimized CMC to produce through our GMP.
Development of a Cure for Untreatable Diseases
MicrobiotiX aims to develop various treatments for untreatable diseases through bacteriophages that can target gram-negative, multidrug-resistant bacteria and through microbiome modulation to treat: pneumonia, sepsis, IBD, autism, obesity, diabetes, colon cancer, etc.
MP001 - Pneumonia
Including cystic fibrosis
Composition Fixed rate cocktail of 3 types of phages
Clinical use indications acute pneumonia infected with multidrug-resistant P. aeruginosa
Genetic modification natural, unmodified lytic bacteriophages
Target patient (Sputum bacterium culture) All age groups shedding P. aeruginosa in sputum
Dosage form liquid, 10 mL vial Combined administration Meropenem and others Storage duration and method After 2 years, a 1/10 tier reduction, 5 Celsius
PK/PD (half-life) 2~12 hours in a healthy person Usage and dosage amount 1x10^ ~ 5x10^9 CFU/ml bid (1Day 2times) / tid (1Day 3times) (for 2weeks) Route of administration intravenous shot
Safety Total AE occurrence, minimal to minor adverse events <10% (from treated patients)
In-vitro phage efficacy evaluation factors burst size (greater than 10 for each infected bacteria), latent period (less than 2 hours), and adsorption rate (less than 1x10^8 ml/hr)
Product MP003 - MP009
Urinary Tract Infection
CMC(Chemical Manufacturing and Controls)